ERBB2 and ovarian carcinoma: Moreover, we analysed TCR chain rearrangements and Her2/neu expression to determine whether the generally accepted prognostic benefit of T lymphocytes in ovarian carcinomas (Zhang et al, 2003; Curiel et al, 2004; Raspollini et al, 2005; Sato et al, 2005; Hamanishi et al, 2007; Tomsová et al, 2008; Clarke et al, 2009; Leffers et al, 2009) is caused by a specific (re-)activation of individual clonally restricted TILs within the tumour parenchyma by HER2/neu-expressing tumour cells.